为啥5元流感疫苗打不动，200元流感药抢着要？

Core Viewpoint - The article highlights the low flu vaccine uptake in China, driven by widespread vaccine hesitancy among the population, including healthcare professionals, despite the availability of free vaccines for vulnerable groups [1][6][14]. Group 1: Vaccine Market Dynamics - The three main companies relying on flu vaccine sales in China are Hualan Biological (10.7 billion), Zhonghui Biological (2.6 billion), and Jindike (808 million), with a combined annual sales of approximately 14 billion [3]. - In contrast, the leading flu medication company, Dongyangguang Pharmaceutical, reported annual sales of around 26 billion for its flu drug Oseltamivir [3]. - The article notes a significant disparity between the sales of flu vaccines and flu medications, with the latter being preferred by consumers due to immediate symptom relief [3][13]. Group 2: Reasons for Vaccine Hesitancy - Vaccine hesitancy is attributed to several factors, including doubts about vaccine effectiveness and safety, as well as a lack of awareness regarding the severity of flu [9][10]. - Many individuals, including healthcare workers, express skepticism about the flu vaccine's ability to prevent infection, leading them to rely on medications instead [9][10]. - A study indicated that over half of social media users exhibit flu vaccine hesitancy, primarily due to distrust in vaccine efficacy and safety [10][11]. Group 3: Public Health Implications - The low flu vaccine uptake has resulted in significant public health concerns, with over 200,000 excess deaths related to flu annually in China [14]. - The Chinese flu vaccine uptake rate remains around 3%, which is significantly lower than global averages, highlighting the urgent need for improved public health strategies [14][16]. - Recent initiatives by health authorities aim to enhance vaccine accessibility and encourage healthcare workers to lead by example in promoting flu vaccination [16].